Read Taconic's response to coronavirus (COVID-19), and visit our toolkit for researchers. Learn More

huNOG

Constitutive Knockout

huNOG Humanized Mouse Model
Now available from US and EU production sites.

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • HSCCB-NOG-F
    sp/sp;ko/ko
    NOD.Cg-Prkdcscid Il2rgtm1Sug/ JicTac
  • HSCFTL-NOG-F
    sp/sp;ko/ko
    NOD.Cg-Prkdcscid Il2rgtm1Sug/ JicTac
  • NOG mice engrafted with human CD34+ hematopoietic stem cells (HSCs) stably develop multiple cell lineages by 12-16 weeks post-injection.
  • Human lymphocytes are present in peripheral blood, bone marrow, thymus and spleen.
  • Long term studies are possible in huNOG mice, with literature reports of stable engraftment and hematopoiesis for one year or more. However, not all human immune cell types are present, and some cell types may not be completely functional.

Taconic maintains an inventory of female huNOG mice engrafted as juveniles and FACS tested around 12 weeks post-engraftment; all mice are ≥25% hCD45+ in peripheral blood. Custom options for huNOG generation and assessment of engraftment are available, such as HLA matching and age of engraftment.

Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Related Taconic InsightRead the Related Taconic Biosciences' Insight:

Color:

Albino

Species:

Mouse


Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758

Conditions of Use specific to models generated using CRISPR/Cas9
This Model was generated using CRISPR/Cas9 technology. Taconic uses CRISPR/Cas9 technology to generate and/or distribute gene-edited models under licenses from The Broad Institute, Inc., the Massachusetts Institute of Technology, the President and Fellows of Harvard College, the University of Iowa Research Foundation and ERS Genomics. View the full list of licensed patents:
  • This Model and biological materials derived from it may only be used for purchasers' internal research purposes in the Field, unless purchaser otherwise has rights from the Broad covering such use. "Field" means use as a research tool for research purposes, and expressly excludes any (a) clinical use, (b) human, veterinary, livestock or agricultural use, or (c) manufacture, distribution, sale, promotion, use or other exploitation as a testing service, therapeutic or diagnostic for humans or animals.
  • The Models and biological materials derived from them will not be sold or used to perform services for third parties (unless purchaser is acting on behalf of a third party to which they have communicated these Conditions of Use and which third party has accepted these Conditions of Use), or otherwise used for commercial purposes.
  • Purchasers will only use the Models and biological materials derived from them in compliance with all applicable laws and regulations, including applicable human health and animal welfare laws and regulations.
  • Each non-profit purchaser agrees that it, and not Taconic's licensors, shall be responsible for any liability, damage, loss or expense arising out of or related to purchaser's use of the purchased Models and any biological materials derived from them , including any breach of the Label License "Conditions of Use for Taconic Transgenic Models" by purchaser.
  • Each for-profit purchaser further agrees that it shall indemnify, defend and hold harmless Taconic's licensors against any liability, damage, loss, or expense (including without limitation reasonable attorneys' fees and expenses) incurred by or imposed upon any of Taconic's licensors in connection with any claims, suits, investigations, actions, demands or judgments arising out of or related to purchaser's use of the purchased Models and any biological materials derived from them.
  • Each purchaser acknowledges that the purchased Models and any biological materials derived from them and its use may be the subject of one or more issued patents and/or pending patent applications owned by Taconic's licensors, and the purchase of the Models does not convey a license under any claims in the foregoing patents or patent applications.

Humanized NOG Mice are Replete with Human B Cells and CD3+ T Cells

Flow cytometry analysis of human cell lineages in huNOG mice

Flow cytometry analysis of human cell lineages in huNOG mice
Figure 1: (a) Representative flow cytometry plot of the human (hCD45+) cell to mouse cell (mCD45+) ratio at 12 weeks post engraftment. (b) Relative percentage of human cells expressing the B cell marker CD20 vs the T cell marker CD3. (c) Consistent engraftment ratios of greater than 25% hCD45+ cells in over 80 percent of animals (n=91), with highly reproducible relative T cell and B cell enrichment levels. Each dot represents an individual mouse analyzed by flow cytometry 12 weeks post CD34+ HSC engraftment.

Oncology & Immunotherapy Research with huNOG Mice

Combinatory treatment of oncolytic adenovirus with anti PD-1 shows synergistic anti-tumor effect in huNOG tumor model

Combinatory treatment of oncolytic adenovirus with anti PD-1 shows synergistic anti-tumor effect in huNOG tumor model
Figure 2: Effects of ONCOS-102 and pembrolizumab treatments on tumor volume of A2058 engrafted huNOG mice. (a) Tumor volume on day 26 for right and left tumor. (b) Tumor volume on day 40 for right and left tumor. (c) Tumor volume throughout the treatment (pooled for right and left tumors). (d) Tumor volume on day 40 (pooled for right and left tumors). Adapted from Kuryk, et al. 2019 under Creative Commons Attribution License.

Human immune system increases breast cancer-induced osteoblastic bone growth in huNOG mice

Human immune system increases breast cancer-induced osteoblastic bone growth in huNOG mice
Figure 3: Tumor-induced bone changes in NOG and huNOG mice. (a) Quantification of the bone lesion area from X-ray imaging (b) at 4, 6, and 8 weeks after cancer cell inoculation. (c) BMD in the tumor-bearing tibia relative to BMD in the healthy tibia. Adapted from Kähkönen, et al. 2019 under Creative Commons Attribution License.